Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
Status:
Completed
Trial end date:
2020-06-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety, tolerability, and immunogenicity of
Personalized Genomic Vaccine 001 (PGV001) in subjects with advanced non-hematologic
malignancies. PGV001 is a peptide vaccine that is based on a patient's own tumor sequence.
Each patient's tumor is sequenced and peptides that correspond to the tumors are made. These
peptides combined with the adjuvant Poly-ICLC (Hiltonol®, Oncovir) make PGV001. The adjuvant
Poly-ICLC is added to boost the immune response to the peptides and together will expand
immune cells to target cancer.